Literature DB >> 27171617

Refinement and revalidation of the demoralization scale: The DS-II-internal validity.

Sophie Robinson1,2, David W Kissane1,3,4,5, Joanne Brooker1,3, Natasha Michael4,6, Jane Fischer7, Michael Franco5,6, Courtney Hempton1,3, Merlina Sulistio4, Julie F Pallant8, David M Clarke1, Susan Burney2,3.   

Abstract

BACKGROUND: The Demoralization Scale (DS) was initially validated in 2004 to enable the measurement of demoralization in patients with advanced cancer. Subsequent shortcomings indicated the need for psychometric strengthening. Here, the authors report on the refinement and revalidation of the DS to form the DS-II, specifically reporting the scale's internal validity.
METHODS: Patients with cancer or other progressive diseases who were receiving palliative care (n = 211) completed a revised version of the 24-item DS and a measure of symptom burden (the Memorial Symptom Assessment Scale). Exploratory factor analysis and Rasch modeling were used to evaluate, modify, and revalidate the scale, providing information about dimensionality, suitability of response format, item fit, item bias, and item difficulty. Test-retest reliability was examined for 58 symptomatically stable patients at a 5-day follow-up.
RESULTS: Exploratory factor analysis supported a 22-item, 2-component model. Separate Rasch modeling of each component resulted in collapsing the response option categories and removing 3 items from each component. Both final 8-item subscales met Rasch model expectations and were appropriate to sum as a 16-item total score. The DS-II demonstrated internal consistency and test-retest reliability (Meaning and Purpose subscale: α = .84; intraclass correlation [ICC] = 0.68; Distress and Coping Ability subscale: α = .82; ICC = 0.82; total DS: α = .89; ICC = 0.80).
CONCLUSIONS: The DS-II is a 3-point response, self-report scale comprising 16 items and 2 subscales. Given its revalidation, psychometric strengthening, and simplification, the DS-II is an improved and more practical measure of demoralization for research and clinical use. External validation of the DS-II will be reported subsequently. Cancer 2016;122:2251-9.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  Rasch modeling; adjustment; cancer; coping behavior; demoralization; psychometrics; reliability; validity

Mesh:

Year:  2016        PMID: 27171617     DOI: 10.1002/cncr.30015

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  A cross-sectional study on demoralization in prostate cancer patients: the role of masculine self-esteem, depression, and resilience.

Authors:  Cristiano Scandurra; Francesco Mangiapia; Roberto La Rocca; Francesco Di Bello; Natascia De Lucia; Benedetta Muzii; Micaela Cantone; Rita Zampi; Gianluigi Califano; Nelson Mauro Maldonato; Nicola Longo
Journal:  Support Care Cancer       Date:  2022-05-18       Impact factor: 3.359

2.  Incidence and risk factors for suicidal ideation in a sample of Chinese patients with mixed cancer types.

Authors:  Qianlin Lai; Hong Huang; Yinting Zhu; Siwei Shu; Yaner Chen; Yuanyuan Luo; Lili Zhang; Zhihui Yang
Journal:  Support Care Cancer       Date:  2022-10-21       Impact factor: 3.359

3.  Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients.

Authors:  Andrew S Huhn; Mary M Sweeney; Robert K Brooner; Michael S Kidorf; D Andrew Tompkins; Hasan Ayaz; Kelly E Dunn
Journal:  Neuropsychopharmacology       Date:  2018-10-30       Impact factor: 7.853

4.  Existential distress in patients with advanced cancer and their caregivers: study protocol of a longitudinal cohort study.

Authors:  Rebecca Philipp; Anna Kalender; Martin Härter; Carsten Bokemeyer; Karin Oechsle; Uwe Koch; Sigrun Vehling
Journal:  BMJ Open       Date:  2021-04-24       Impact factor: 2.692

5.  Psychometric Evaluation of the German Version of the Demoralization Scale-II and the Association Between Demoralization, Sociodemographic, Disease- and Treatment-Related Factors in Patients With Cancer.

Authors:  Susan Koranyi; Andreas Hinz; Julia M Hufeld; Tim J Hartung; Leonhard Quintero Garzón; Uta Fendel; Anne Letsch; Matthias Rose; Peter Esser; Anja Mehnert-Theuerkauf
Journal:  Front Psychol       Date:  2021-11-24

6.  Demoralisation and its link with depression, psychological adjustment and suicidality among cancer patients: A network psychometrics approach.

Authors:  Irene Bobevski; David W Kissane; Sigrun Vehling; Anja Mehnert-Theuerkauf; Martino Belvederi Murri; Luigi Grassi
Journal:  Cancer Med       Date:  2021-12-04       Impact factor: 4.452

Review 7.  Psychological Aspects of Care in Cancer Patients in the Last Weeks/Days of Life.

Authors:  Sujin Ann-Yi; Eduardo Bruera
Journal:  Cancer Res Treat       Date:  2022-06-28       Impact factor: 5.036

8.  Medical Assistance in Dying in patients with advanced cancer and their caregivers: a mixed methods longitudinal study protocol.

Authors:  Madeline Li; Gilla K Shapiro; Roberta Klein; Anne Barbeau; Anne Rydall; Jennifer A H Bell; Rinat Nissim; Sarah Hales; Camilla Zimmermann; Rebecca K S Wong; Gary Rodin
Journal:  BMC Palliat Care       Date:  2021-07-21       Impact factor: 3.234

9.  The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone.

Authors:  Andrew S Huhn; Robert K Brooner; Mary M Sweeney; Denis Antoine; Alexis S Hammond; Hasan Ayaz; Kelly E Dunn
Journal:  Addict Behav       Date:  2020-09-28       Impact factor: 3.913

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.